Product Center
The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-05-08
- Views:
(Summary description)Recently, the IND application for a Class 1 new drug— "Respiratory Syncytial Virus mRNA Vaccine" —jointly submitted by Ab&B Bio-Tech Co. Ltd. JS (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating.
(Summary description)Recently, the IND application for a Class 1 new drug— "Respiratory Syncytial Virus mRNA Vaccine" —jointly submitted by Ab&B Bio-Tech Co. Ltd. JS (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-05-08 15:49
- Views:
Recently, the IND application for a Class 1 new drug— "Respiratory Syncytial Virus mRNA Vaccine" —jointly submitted by Ab&B Bio-Tech Co. Ltd. JS (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
Of particular note is that this vaccine has also obtained clinical trial approval from the U.S. FDA, demonstrating its global development potential. This marks another product of the company to receive dual regulatory approvals for clinical trials in both China and the United States, fully showcasing its outstanding R&D capabilities and international strategic footprint, while further highlighting the company's steadfast commitment and confidence in implementing its overseas expansion strategy.
Following the approval of its respiratory syncytial virus mRNA vaccine clinical trial application by the U.S. Food and Drug Administration (FDA), the company has now received further approval from the Center for Drug Evaluation of the China National Medical Products Administration. This achievement not only marks another milestone for the company's mRNA technology platform but also demonstrates its growing maturity, laying a solid foundation for Ab&B Bio's future in-depth expansion and product iteration in the mRNA technology field.
The sustained output of innovative achievements is attributed to the company's forward-looking deployment of the mRNA technology platform. The core advantages of this platform lie in its agile R&D capabilities and scalable production potential. As a "digital" platform, it enables rapid design and synthesis upon obtaining the target sequence, facilitating swift iteration. In terms of safety, mRNA does not enter the cell nucleus, eliminating the risk of genomic integration. Regarding efficacy, through sequence optimization and advanced delivery systems, it simultaneously activates robust humoral and cellular immunity.
Currently, the company has accumulated substantial technical expertise in developing mRNA vaccines targeting single pathogens in the field of infectious disease vaccines. In addition to its existing products—the RSV mRNA vaccine and the monkeypox virus mRNA vaccine—the company is rapidly expanding its efforts toward developing combination mRNA vaccines targeting multiple pathogens. It is also applying mRNA/LNP technology to the development of innovative cancer therapies and treatments for autoimmune diseases. Concurrently, the company is actively leveraging AI technologies to enhance the design and development of neoantigens, targeting the broader biomedical frontier represented by preventive vaccines for infectious diseases and therapeutic vaccines for conditions such as cancer.
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
